Hungary-based Mediso has completed the first phase of a major technology transfer from Superconducting Systems Inc. (SSI), a subsidiary of IMRIS, marking a pivotal step toward full vertical integration of its MRI system development. The agreement allows Mediso to bring cryogen-free superconducting magnet production in-house, targeting field strengths up to 9.4 Tesla.

Mediso has been a longtime user of SSI’s helium-free magnet technology in its nanoScan® 3T and 7T MRI systems, widely used in preclinical imaging. With this transfer, Mediso now gains access to SSI’s intellectual property, enabling it to design and manufacture conduction-cooled MRI magnets tailored to a variety of bore sizes and use cases.

The company is scaling up its European manufacturing capacity, with full-scale production set to begin by the end of 2025. This move allows Mediso to integrate magnet design into its established quality management systems, enhancing flexibility and innovation across its imaging platforms.

Mediso aims to extend the impact of compact and cryogen-free MRI globally, with plans to develop next-generation systems for both research and clinical use.

MedTech Summary:

• Mediso completes tech transfer of cryogen-free MRI magnet technology from SSI.

• Enables in-house development of superconducting magnets up to 9.4T without liquid helium.

• Full-scale European manufacturing to be operational by year-end 2025.